Sheila Mikhail, CEO
Research Triangle Park, NC
Founded in 2001 by gene therapy pioneers, Asklepios BioPharmaceutical is a fully-integrated, privately-held gene therapy company with global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, UK. We are dedicated to develop life saving medicines that cure genetic disease. Our clinical-stage programs include Pompe disease and congestive heart failure, as well as out-licensed clinical indications for hemophilia (Chatham Therapeutics acquired by Takeda) and Duchenne muscular dystrophy (Bamboo Therapeutics acquired by Pfizer). Our AAV gene therapy platform includes Pro10™, an industry-leading, proprietary cell line manufacturing process, and an extensive AAV capsid and promoter library. An early innovator in the space, AskBio holds more than 500 patents in areas such as AAV production, and chimeric and self-complementary capsids.

By using this website you agree to accept our Privacy Policy and Terms & Conditions